Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.40 |
| ▸ | SCN1A | P35498 | 6/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 6/20 | 0.39 |
| ▸ | SCN8A | Q9UQD0 | 6/20 | 0.39 |
| ▸ | KRAS | P01116 | 1/20 | 0.38 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | TNF | P01375 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18483511 | 1.00 | CYP2C19 (0.46) | CYP2C19HPGDHSD17B10KDM4EHTR6 | |
| SCHEMBL18483206 | 0.80 | ALDH1A1 (0.55) | HPGDHSD17B10ALDH1A1GAARAB9A | |
| SCHEMBL18449481 | 0.80 | ALDH1A1 (0.55) | HPGDHSD17B10ALDH1A1GAARAB9A | |
| SCHEMBL19205648 | 0.80 | ALDH1A1 (0.55) | HPGDHSD17B10ALDH1A1GAARAB9A | |
| SCHEMBL18484164 | 0.78 | PIK3CD (0.39) | CYP2C19HPGDHSD17B10KDM4EP2RX3 | |
| SCHEMBL19205792 | 0.78 | PIK3CD (0.39) | CYP2C19HPGDHSD17B10KDM4EP2RX3 | |
| SCHEMBL11109382 | 0.77 | P2RX3 (0.47) | CYP2C19KDM4EHTR6P2RX3SCN1A | |
| SCHEMBL19205818 | 0.73 | ATP1A1 (0.49) | HPGDKDM4EP2RX3ADRB2ALDH1A1 | |
| SCHEMBL19205819 | 0.73 | ATP1A1 (0.49) | HPGDKDM4EP2RX3ADRB2ALDH1A1 | |
| SCHEMBL18484101 | 0.73 | KMT2A (0.44) | CYP2C19HPGDKDM4ESCN1ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108026050-B | Novel compounds as ROR gamma modulators | 格兰马克药品股份有限公司 | 2021-04-30 | — | — | CN | disclosed |
| US-10988467-B2 | Compounds as ROR gamma modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2021-04-27 | — | — | US | disclosed |
| EP-3686187-A1 | PROCESS FOR THE PREPARATION OF ROR GAMMA MODULATORS | Glenmark Pharmaceuticals S.A. (CH) | 2020-07-29 | — | — | EP | disclosed |
| EP-3686187-A1 | PROCESS FOR THE PREPARATION OF ROR GAMMA MODULATORS | Glenmark Pharmaceuticals S.A. (CH) | 2020-07-29 | — | — | EP | disclosed |
| EP-3331863-B1 | NOVEL COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2020-03-11 | — | — | EP | disclosed |
| US-20190256508-A1 | NOVEL COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2019-08-22 | — | — | US | disclosed |
| US-10344024-B2 | Compounds as ROR gamma modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2019-07-09 | — | — | US | disclosed |
| US-20180237428-A1 | NOVEL COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2018-08-23 | — | — | US | disclosed |
| US-9975887-B2 | Compounds as ROR gamma modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2018-05-22 | — | — | US | disclosed |
| US-20170233380-A1 | NOVEL COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10988467-B2 | Compounds as ROR gamma modulators | RORB, RORA, RORC | CYP2C19 1726/4885HPGD 2536/4885HSD17B10 2649/4885 |
| US-10344024-B2 | Compounds as ROR gamma modulators | RORB, RORA, RORC | CYP2C19 1726/4885HPGD 2536/4885HSD17B10 2649/4885 |
| US-20190256508-A1 | NOVEL COMPOUNDS AS ROR GAMMA MODULATORS | RORB, RORA, RORC | CYP2C19 1925/4885HPGD 2735/4885HSD17B10 2625/4885 |
| US-20180237428-A1 | NOVEL COMPOUNDS AS ROR GAMMA MODULATORS | RORB, RORA, RORC | CYP2C19 2270/4885HPGD 2879/4885HSD17B10 2445/4885 |
| US-20170233380-A1 | NOVEL COMPOUNDS AS ROR GAMMA MODULATORS | RORB, RORA, RORC | CYP2C19 1925/4885HPGD 2735/4885HSD17B10 2625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.